The BalancedInvestor Club

AXGN Market Analysis

Overview

Fundamentals

P/E ratio—Forward 370.37
EPS (TTM)$-0.640.0% YoY
Profit margin-13.2%HEALTHCARE
Market cap$2.30BMid cap

Wall Street coverage

$50.78median target· current $5.67 (+795.6%)9 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
370.37
PEG ratio
99.04
P/B
9.40
P/S (TTM)
9.67
EV/EBITDA
4083.53

Profitability & growth

ROE (TTM)
-18.0%
Operating margin
-4.6%
Revenue growth YoY
26.6%
Dividend yield
—
Beta
0.98
Last earnings
Mar 31, 2026 · Estimate $0.07 · Reported $0.07
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Axogen Inc

AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.

Classification

Sector
Healthcare
Industry
Medical Devices
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
13631 PROGRESS BOULEVARD, ALACHUA, FL
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$2.30B
Shares outstanding$53.2M
52W high$45.83
52W low$9.22

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer